BOLT
Bolt Biotherapeutics, Inc.
-0.33 (-9.09%)3.30USD36.9K成交股數6.4M市值–本益比(近四季)1.4股價營收比-99.7%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 5K-100% | 26K | 2.2M+90% | 1.8M+41% | 1.2M-77% | 0.00-100% | 1.1M-20% | 1.3M-30% | 5.3M | 2.5M | 1.4M | 1.8M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 5.1M | 4.8M | 6.5M | 7.5M | 9.5M | 11.7M | 13.8M | 15.4M | 16.5M | 15.0M | 15.6M | 14.6M |
| 銷售管理費用 | 2.4M | 2.8M | 3.3M | 3.5M | 3.8M | 3.9M | 3.8M | 4.9M | 5.8M | 5.8M | 5.6M | 5.6M |
| 營業利益 | −8.4M-31% | −7.6M-55% | −7.7M-53% | −9.2M-59% | −12.1M-29% | −16.9M-7% | −16.4M-17% | −22.6M+23% | −17.1M | −18.2M | −19.8M | −18.4M |
| 營業利益率 | -167,480.0% | -29,234.6% | -355.1% | -510.5% | -991.4% | – | -1,441.1% | -1,772.3% | -324.1% | -719.3% | -1,383.9% | -1,008.5% |
| 稅後淨利 | −7.7M-30% | −7.2M-55% | −7.1M-53% | −8.6M-60% | −11.0M+2% | −15.9M-2% | −15.2M-16% | −21.2M+25% | −10.8M | −16.3M | −18.1M | −17.0M |
| 淨利率 | -154,400.0% | -27,861.5% | -329.4% | -474.6% | -903.4% | – | -1,330.1% | -1,662.4% | -205.0% | -643.1% | -1,260.1% | -929.9% |
| 稀釋 EPS | -4.57-21% | -4.31-69% | -3.72-53% | -4.46-60% | -5.76+1957% | -13.73+3093% | -7.93+1552% | -11.12+2371% | -0.28 | -0.43 | -0.48 | -0.45 |
| 稀釋股數 | 1.7M | 1.7M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M | 38.1M | 37.9M | 37.8M | 37.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 12.9M | 11.6M | 17.8M | 9.6M | 8.4M | 7.2M | 9.4M | 6.2M | 4.3M | 9.2M | 13.5M | 14.8M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 40.3M | 48.0M | 65.1M | 75.5M | 85.9M | 99.6M | 109M | 124M | 143M | 175M | 191M | 206M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 27.7M | 28.2M | 33.0M | 36.7M | 39.1M | 42.4M | 37.3M | 38.3M | 38.7M | 47.1M | 48.6M | 48.5M |
| 股東權益 | 12.6M | 19.8M | 32.1M | 38.8M | 46.8M | 57.2M | 72.0M | 85.9M | 104M | 128M | 142M | 158M |
| 負債比 | 68.7% | 58.7% | 50.7% | 48.6% | 45.5% | 42.6% | 34.1% | 30.9% | 27.1% | 26.9% | 25.5% | 23.5% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −8.0M | – | – | −13.4M-20% | – | – | – | −16.8M | – | – | −23.4M |
| 資本支出 | – | – | – | – | – | – | – | – | 0.00 | – | – | 3K |
| 自由現金流 | – | – | – | – | – | – | – | – | −16.8M | – | – | −23.4M |
| 折舊攤銷 | – | 203K | – | – | 399K | – | – | – | 458K | – | – | 467K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -317.6% | – | – | -1,281.6% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 7.7M | +0.1% | −33.4M | -433.7% | -17.85 | −39.9M |
| FY2024 | 7.7M | -2.4% | −63.1M | -820.8% | -33.06 | −61.3M |
| FY2023 | 7.9M | +37.5% | −69.2M | -878.6% | -1.83 | −69.7M |
| FY2022 | 5.7M | +354.7% | −88.1M | -1,537.8% | -2.36 | −78.5M |
| FY2021 | 1.3M | +445.5% | −98.6M | -7,824.7% | -2.97 | −59.4M |
| FY2020 | 231K | – | −60.7M | -26,289.2% | -28.89 | −50.6M |